Surprising, existing clinical studies have revealed that GM-CSF is the only adjuvant in conjunction with HER2/neu peptide vaccines in the current breast cancer clinical trials, provided with its greater promising clinical value in treating melanoma, ovarian or prostate cancer than other adjuvants (Clive et al. 2010). Here, CSF2 is linked to prostate carcinoma.